Elizabeth (Beth) Garner is a seasoned pharmaceutical executive with a career-long focus on addressing unmet medical needs for women. Born and raised in Nigeria, she brings a global perspective to her work and leadership. Dr. Garner is currently the CEO of Sena Therapeutics, a start-up company focused on precision medicine for endocrine diseases, with its first indication in Polycystic Ovarian Syndrome. Most recently, she served as the US Chief Scientific Officer of Ferring, a leading mid-size global company focused on reproductive and maternal health, microbiome and gastrointestinal therapeutics, and uro-oncology. From 2019 to 2022, she was the Chief Medical Officer (CMO) of ObsEva, a Swiss company dedicated to addressing unmet needs in women’s health. There, she led the 2022 European Commission marketing authorization of Yselty®, an oral GnRH antagonist for the treatment of uterine fibroids. From 2014 to 2019, Dr. Garner was the CMO of Agile Therapeutics, where she was instrumental in the achievement of the company’s July 2014 IPO and subsequent follow-on offerings. Under her leadership, the company achieved FDA approval for Twirla® (a novel low-dose contraceptive patch).

From 2012 to 2014, Elizabeth served as VP of Medical Affairs at Myriad Genetics, and before that, she was Senior Director at Abbott Laboratories, where she oversaw all clinical aspects of the global Phase 3 endometriosis program for elagolix (Orilissa®). From 2007 to 2011, she was Associate Director, then Director of Clinical Research at Merck. As a leader on the HPV vaccine program, she was a key contributor to important regulatory submissions, served as chair of the Gardasil®9 Product Development Team, leading scientific, regulatory, market access, and medical affairs strategies, and was substantially involved in HPV vaccine commercialisation strategy. Elizabeth’s industry experience also includes participation in three FDA Advisory Committee meetings, all of which resulted in positive outcomes and subsequent FDA approvals.

Dr. Garner sits on the Board of Directors (BOD) of Kezar Life Sciences and serves as the BOD chair of NUA Surgical, a start-up dedicated to surgical solutions in women's health. She is the Founder and President of KNI Health Consultants, LLC, which provides clinical and regulatory consulting to life science companies. She is also a Past President of the American Medical Women’s Association, a professional organization for women doctors, and a Founder and Steering Committee member of Women’s Health Advocates, an organization dedicated to improving the health of women. Beth received joint M.D. and M.P.H. degrees from Harvard Medical and Public Health Schools, trained in obstetrics and gynecology at Brigham and Women’s (BWH)/Massachusetts General Hospitals, and completed a fellowship in gynecologic oncology at BWH/Dana-Farber Cancer Institute.